Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.35 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.35 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.35 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1708176 | 0.78 | L3MBTL1 (0.38) | L3MBTL1ALDH1A1TSHRTLR8THRB | |
| SCHEMBL1708381 | 0.75 | BMI1 (0.40) | L3MBTL1TSHR | |
| SCHEMBL1708065 | 0.71 | TSHR (0.59) | L3MBTL1ALDH1A1TSHRPIK3CDPDCD1 | |
| SCHEMBL1625073 | 0.71 | MEN1 (0.44) | TLR8 | |
| SCHEMBL11166064 | 0.70 | PDCD1 (0.47) | L3MBTL1ALDH1A1THRBPDCD1CD274 | |
| SCHEMBL11038477 | 0.70 | PDE10A (0.42) | L3MBTL1ALDH1A1TLR8PDE10A | |
| SCHEMBL14305182 | 0.69 | L3MBTL1 (0.67) | L3MBTL1ALDH1A1CYP2C19PDE10A | |
| SCHEMBL21621709 | 0.69 | PDCD1 (0.40) | ALDH1A1TSHRPDCD1CD274 | |
| SCHEMBL17945686 | 0.67 | L3MBTL1 (0.41) | L3MBTL1ALDH1A1TSHRPIK3CD | |
| SCHEMBL17994368 | 0.67 | L3MBTL1 (0.41) | L3MBTL1ALDH1A1TSHRCYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120172351-A1 | NOVEL FUSED CYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-07-05 | — | — | US | disclosed |
| EP-2440541-A1 | NOVEL FUSED CYCLIC COMPOUND AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2012-04-18 | — | — | EP | disclosed |
| WO-2010143733-A1 | NOVEL FUSED CYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120172351-A1 | NOVEL FUSED CYCLIC COMPOUND AND USE THEREOF | GPR119, INSR, GLP1R | L3MBTL1 4617/4885ALDH1A1 3930/4885TSHR 637/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.